Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Industry Sees Overhaul of CEA Scheme “Too Early,” Chuikyo Reps Agree
It is too early to make drastic changes to Japan’s fledgling cost-effectiveness assessment (CEA) system at this point, pharma trade groups of Japan, the US, and Europe said on August 4 - a view that was shared with members of…
To read the full story
Related Article
- Chuikyo OKs 2022 Reform Outline for Cost-Effectiveness Assessment System
December 2, 2021
- Pharma Calls for Enhancing Pre-Analysis Discussions in CEA Scheme: Chuikyo
November 15, 2021
- Chuikyo OKs MHLW Proposal on CEA Price Adjustments, Analysis Team Set-Up
October 18, 2021
- Chuikyo Raises No Objections to MHLW Proposal on Revision of CEA Analysis Process
September 17, 2021
- CEA Reform Debate Going into Full Throttle, Chuikyo Consensus to Be Drawn as Early as October
August 3, 2021
REGULATORY
- Govt’s Honebuto Draft Confirms FY2027 Off-Year Drug Price Revision
July 1, 2026
- Govt Presents Growth Strategy Draft Ahead of July Approval
July 1, 2026
- Japan Moves to Add Ceftriaxone to Economic Security List
July 1, 2026
- LDP Group Submits Honebuto Proposal, Urges Pediatric Cancer Platform
July 1, 2026
- Lower House Clears Immunization Act Revision
July 1, 2026
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…